Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (395)	6/5/2003 4:10:28 PM
From: software salesperson	Respond to of 1840

Researchers Successfully Inhibit Spread Of Cancer In Mice Many types of cancer--like those of the breast and prostate--would not be nearly as deadly if it weren't for their ability to spread to vital organs. Still, scientists don't yet fully understand the way in which cancer spreads, or metastasizes, or how to prevent the process. Now, researchers at the San Francisco VA Medical Center (SFVAMC) have used a modified version of a naturally occurring human protein to decrease the spread of human breast cancer implanted in mice. "We were able to significantly reduce the spread of the disease and decrease tumor growth without any evidence of toxicity," said senior author Gary Jarvis, PhD, a SFVAMC microbiologist and UCSF associate professor of laboratory medicine. The current findings appear in the June issue of Clinical Cancer Research, with figures from the paper appearing on its cover. Jarvis credits first author Constance John, PhD, a research chemist in his lab at the time, with coming up with the idea of interfering with the ability of cancer cells to stick to one another as a way of attacking metastasis. The ability to adhere to other cells is what allows a cell that breaks away from a primary tumor to lodge in other parts of the body. "It's when tumors spread to essential organs, such as the liver or lung, that they become fatal. There is nothing to date that has been approved by the FDA for treatment of cancer that works on that process," said John. John, who is no longer affiliated with SFVAMC, is currently the president of MandalMed, Inc., a San Francisco-based company working to develop a drug that inhibits metastasis based on these findings. (Jarvis, of SFVAMC/UCSF, has no financial stake in MandalMed.) A drug that could reduce metastasis would greatly improve upon the beneficial outcomes already achieved with chemotherapy, surgery and radiation, John said. "We're not trying to develop a cure for cancer. What we're trying to do is make cancer a disease that one can live with," she said. As a way of targeting metastasis, John proposed modifying a human protein known as galectin-3, a member of the family of proteins called lectins that bind to sugar molecules on the surfaces of cells. Galectin-3 is known to play multiple roles in cancer formation, including the promotion of cell-to-cell adhesion, or sticking. "The idea was to break that contact and inhibit secondary cancer formation," Jarvis said. The researchers left the sugar-binding region of galectin-3 intact, but removed the part of the protein that normally allows cells to stick to one another. They then implanted portions of human-derived breast cancer tumors into the chest pads of nude mice, mice having a low-functioning immune system. Once the tumors were established, they injected the experimental animals with truncated galectin-3. The control mice were given sham injections. By the end of the experiment, the team found that cancer had spread to lymph nodes or other organs in four out of 20 experimental mice versus 11 of 20 control mice. In addition, the post-treatment growth of the implanted tumor fragments was significantly less than in the control animals. Monitoring the animals during this and additional experiments showed that the modified protein did not cause any apparent adverse effects or death in the mice. Jarvis believes that the modified version of galectin-3 was able to interfere with the breast cancer cells' ability to stick to one another and to the healthy cells of other organs. "The data supports the hypotheses that truncated galectin-3 inhibits the process of metastasis," he said. Jarvis and his colleagues at the SFVAMC are currently working on the functional studies that would determine the mechanism behind the reduction in metastasis they observed. Jarvis said a drug therapy targeting galectin-3 activity might someday be effectively used in combination with currently available cancer medications. "If we can stop metastasis in humans, we will have gone a long way towards successfully treating cancer," he said. Jarvis and his colleagues at the SFVAMC have since repeated these results and plan to extend the current study by looking at different types of cancer and different truncated versions of galectin-3 in combination with currently available anticancer medications.

To: Icebrg who wrote (395)	6/5/2003 5:18:39 PM
From: Icebrg	Read Replies (1) \| Respond to of 1840

I have posted a number of individual articles on new ASCO follow-ups, which are available at Medscape. Now it turns out that there is a summary article where all the individual interviews are linked from. I didn't notice this as my rss-agent doesn't always present things in an logical order. Anyhow, this is the summary of articles available on Medscape. Erik medscape.com American Society of Clinical Oncology 39th Annual Meeting Expert Interviews May 31, 2003 - June 3, 2003, Chicago, Illinois This activity is not sanctioned by, nor a part of, the American Society of Clinical Oncology. Contents 1. Targeted Therapies in Lung Cancer: An interview with Vincent A. Miller, MD Eric Sabo 2. Update on Prostate Cancer: An interview with Howard Sandler, MD Emma Hitt, PhD 3. Treatment of Head and Neck Cancers: An interview with Marshall R. Posner, MD Mary Beth Nierengarten, MA 4. Hormonal and Targeted Therapies in Breast Cancer: An interview with Harold J. Burstein, MD, PhD Mary Beth Nierengarten, MA 5. Advances in Gynecologic Malignancies: An interview with Gini Florence Fleming, MD Emma Hitt, PhD 6. Update on Gastrointestinal Cancer: An Interview With Charles S. Fuchs, MD Shira Berman 7. Chemotherapeutic Options for Lung Cancer: An Interview With Mark R. Green, MD Emma Hitt, PhD 8. Chemotherapy Options for Breast Cancer: An Interview With Clifford A. Hudis, MD Shira Berman 9. Angiogenesis Inhibitors in the Treatment of Cancer: An Interview With Lee S. Rosen, MD Eric Sabo